Highlights bei gastrointestinalen Tumoren

Im Video besprochene Studien

Nivolumab plus Ipilimumab beim Mikrosatelliten-instabilen/Mismatch-Repair-defizienten Kolorektalkarzinom: Final overall survival results from CheckMate 8HW: Nivolumab plus ipilimumab versus nivolumab or chemotherapy in MSI-H/dMMR metastatic colorectal cancer. Lonardi S et al., ESMO 2026, Abstract LBA32.

 Lonardi S et al. Final results of nivolumab plus ipilimumab versus nivolumab or chemotherapy in microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer from CheckMate 8HW. Lonardi S et al., Ann Oncol. Published online October 24, 2026. doi:10.1016/j.annonc.2026.09.009.

Daraxonrasib beim Pankreaskarzinom: Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Additional subgroup analyses from the Phase 3 RASolute 302 study. Wainberg ZA et al., ESMO 2026, Abstract LBA82.

 O’Reilly EM et al. Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. N Engl J Med. 2026;395:325–337. doi:10.1056/NEJMoa2605555.